Skip to content
This repository was archived by the owner on Jun 12, 2026. It is now read-only.
This repository was archived by the owner on Jun 12, 2026. It is now read-only.

SPL Intent-Use categories for Treatment Modality #184

Description

@southalln

FDA's SPL contains information on the intended use of products that corresponds nicely to Treament Modality in Inxight.

https://www.fda.gov/industry/structured-product-labeling-resources/intent-use

I forget how this information comes from FRDB - but one might be able to supplement it with FDA SPL data.

Primary
Substance halts or slows disease progression. Treatment often targets the primary pathology of a disease.
Preventing
Substance is intended to prevent the development of a medical condition.
Palliative
Substance improves the quality of life by alleviating the associated symptoms, without necessarily affecting the underlying pathology.
Secondary
Substance treats adverse effects associated with the treatment of a condition.
Diagnostic
A substance used for diagnostic purposes, including disease detection and monitoring of disease progression.
Inactive Ingredient
An ingredient of a given formulation (most frequently, an excipient) that does not exhibit pharmacological activity. In this case, a condition is only related to such compound via the formulation used to affect (treat or diagnose) this condition.

Activity

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment

Metadata

Metadata

Assignees

No one assigned

    Labels

    No labels
    No labels

    Type

    No type

    Projects

    No projects

      Milestone

      No milestone

      Relationships

      None yet

      Development

      No branches or pull requests

      Issue actions